| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |




From the Departments of Pathology* and Orthopaedic Surgery
and the School of Nursing,
Asahikawa Medical College, Asahikawa, Japan; and the Department of Pathology and Molecular Medicine,
McMaster University, Hamilton, Ontario, Canada
DAP12 (also known as KARAP) is a novel ITAM-bearing transmembrane adapter molecule that is expressed on the cell surface of natural killer cells, monocytes, dendritic cells, and macrophages. Several myeloid cell-specific DAP12-associating receptors, such as TREM receptor family, SIRP-ß1, and MDL-1 have been identified. The in vivo function of DAP12 and its associating molecules in inflammation has remained primarily unknown. To investigate DAP12 signaling during chronic inflammation, we constructed two adenoviral gene transfer vectors to express FLAG/DAP12 (Ad-FDAP12) and the extracellular domain of mouse TREM-1 and the Fc portion of human IgG1 (Ad-TREM-1 Ig), respectively, and observed their modulatory activities in a mouse model of hepatic granulomatous inflammation elicited by zymosan A. Mice were injected with zymosan A intravenously and 24 hours after zymosan A, they were injected with Ad-FDAP12 or Ad-TREM-1 Ig. Zymosan A-induced hepatic granuloma formation peaked at day 7 and markedly declined by day 10. Although adenoviral-mediated DAP12 gene transfer did not enhance granuloma formation by day 7, it sustained and enhanced granuloma formation beyond day 7. However, an anti-FLAG monoclonal antibody used to potentiate the signaling of adenoviral-derived DAP12, enhanced granuloma formation at day 7. In sharp contrast to the effect by Ad-FDAP12, transgene expression in the liver of soluble form of extracellular domain of TREM-1 as an antagonist of DAP12 signaling, remarkably inhibited zymosan A-induced granuloma formation at all time points examined. Our findings thus suggest that both DAP12 and TREM-1 are involved in the development of granulomatous responses in the liver.
This article has been cited by other articles:
![]() |
M. Divangahi, T. Yang, K. Kugathasan, S. McCormick, S. Takenaka, G. Gaschler, A. Ashkar, M. Stampfli, J. Gauldie, J. Bramson, et al. Critical Negative Regulation of Type 1 T Cell Immunity and Immunopathology by Signaling Adaptor DAP12 during Intracellular Infection J. Immunol., September 15, 2007; 179(6): 4015 - 4026. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Murakami, H. Kohsaka, H. Kitasato, and T. Akahoshi Lipopolysaccharide-Induced Up-Regulation of Triggering Receptor Expressed on Myeloid Cells-1 Expression on Macrophages Is Regulated by Endogenous Prostaglandin E2 J. Immunol., January 15, 2007; 178(2): 1144 - 1150. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Fortin, O. Lesur, and T. Fulop Jr Effects of TREM-1 activation in human neutrophils: activation of signaling pathways, recruitment into lipid rafts and association with TLR4 Int. Immunol., January 1, 2007; 19(1): 41 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Carpenter, K. F. Buckland, Z. Xing, and C. M. Hogaboam Intrapulmonary, Adenovirus-Mediated Overexpression of KARAP/DAP12 Enhances Fungal Clearance during Invasive Aspergillosis Infect. Immun., December 1, 2005; 73(12): 8402 - 8406. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. R. Turnbull, J. E. McDunn, T. Takai, R. R. Townsend, J. P. Cobb, and M. Colonna DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis J. Exp. Med., August 1, 2005; 202(3): 363 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schenk, A. Bouchon, S. Birrer, M. Colonna, and C. Mueller Macrophages Expressing Triggering Receptor Expressed on Myeloid Cells-1 Are Underrepresented in the Human Intestine J. Immunol., January 1, 2005; 174(1): 517 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Aoki, A. Zganiacz, P. Margetts, and Z. Xing Differential Regulation of DAP12 and Molecules Associated with DAP12 during Host Responses to Mycobacterial Infection Infect. Immun., May 1, 2004; 72(5): 2477 - 2483. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |